Pictet Asset Management (Switzerland)’s Travere Therapeutics TVTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$30.1M	Buy	1,957,120 +406,618	+26%	+$7.4M	0.04%	375
2023 Q1	$34.9M	Buy	1,550,502 +995,136	+179%	+$21.2M	0.04%	352
2022 Q4	$11.7M	Buy	555,366 +142,855	+35%	+$3.03M	0.02%	559
2022 Q3	$10.2M	Buy	412,511 +59,486	+17%	+$1.54M	0.02%	575
2022 Q2	$8.55M	Buy	353,025 +40,479	+13%	+$1.02M	0.01%	643
2022 Q1	$8.05M	Sell	312,546 -19,042	-6%	-$506K	0.01%	701
2021 Q4	$10.3M	Sell	331,588 -22,575	-6%	-$636K	0.01%	660
2021 Q3	$8.59M	Buy	+354,163	New	+$6.51M	0.01%	708

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s TVTX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Travere Therapeutics (TVTX) stake by 26% in Q2 2023, buying an estimated $7.4M and bringing the position to 1,957,120 shares worth $30.1M. The position accounts for 0.04% of the portfolio, ranked #375.

Pictet Asset Management (Switzerland) first reported a position in TVTX in Q3 2021 and has held it in 8 quarters since. The position peaked at $34.9M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Pictet Asset Management (Switzerland) held 1,957,120 shares of Travere Therapeutics worth $30.1M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 406,618 Travere Therapeutics shares in Q2 2023, an estimated $7.4M.
Travere Therapeutics made up 0.04% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #375 holding.
Pictet Asset Management (Switzerland) first reported a position in Travere Therapeutics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Travere Therapeutics position peaked at $34.9M in Q1 2023.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.